CD86 and bronchiectasis: We noted a significant decrease in the frequency of cDC1s (CD14-CD16-CD1c-) and CD14+CD16− monocytes expressing a range of activation markers including CCR7, IL-12p40, CD86, Ki-67, and TNFα, as a proportion of total CD45+ PBMCs in CPA patients compared to bronchiectasis controls following ZYM stimulation (Supplementary Fig. S3A).